Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 301–400 of 1,015
Zhou, H., Guo, M., Li, J., Qin, F., Wang, Y., Liu, T., Liu, J., Sabet, Z. F., Wang, Y., Liu, Y., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10245 · Cited by 162
Sharma, R., Kadife, E., Myers, M., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01961-3 · Cited by 162
Philip, B., Ito, K., Moreno-Sanchez, R., & Ralph, S. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt209 · Cited by 161
O'Connor, J. P. B., Boult, J. K. R., Jamin, Y., Babur, M., Finegan, K. G., Williams, K. J., Little, R. A., Jackson, A., Parker, G. J. M., Reynolds, A. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2062 · Cited by 161
Zhou, W., Jia, Y., Liu, Y., Chen, Y., & Zhao, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112346 · Cited by 178
Crosstalk of Oncogenic Signaling Pathways during Epithelial–Mesenchymal Transition
Lindsey, S., & Langhans, S. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00358 · Cited by 159
Wang, P., Li, X., Yao, C., Wang, W., Zhao, M., El-Toni, A. M., & Zhang, F. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.017 · Cited by 160
McCullough, D. J., Stabley, J. N., Siemann, D. W., & Behnke, B. J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju036 · Cited by 159
Ferreira, J. A., Peixoto, A., Neves, M., Gaiteiro, C., Reis, C. A., Assaraf, Y. G., & Santos, L. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.003 · Cited by 159
Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Mfuh, A. M., & Larionov, O. V. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150619104007 · Cited by 158
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach-Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 155
Platinum-carbon-integrated nanozymes for enhanced tumor photodynamic and photothermal therapy
Yang, Y., Zhu, D., Liu, Y., Jiang, B., Jiang, W., Yan, X., & Fan, K. (2020) · Nanoscale · doi:10.1039/d0nr02800b · Cited by 156
A Paclitaxel Prodrug Activatable by Irradiation in a Hypoxic Microenvironment
Zhou, S., Hu, X., Xia, R., Liu, S., Pei, Q., Chen, G., Xie, Z., & Jing, X. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008732 · Cited by 156
Conjugated Photosensitizers for Imaging and PDT in Cancer Research
Simões, J. C. S., Sarpaki, S., Papadimitroulas, P., Therrien, B., & Loudos, G. K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00047 · Cited by 171
Bioorthogonal chemistry for prodrug activation in vivo
Fu, Q., Shen, S., Sun, P., 谷, 知., Bai, Y., Wang, X., & Liu, Z. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00889k · Cited by 173
Zou, M., Liu, W., Li, C., Zheng, D., Zeng, J., Gao, F., Ye, J., & Zhang, X. (2018) · Small · doi:10.1002/smll.201801120 · Cited by 155
Mechanical Forces in Tumor Angiogenesis
Zanotelli, M. R., & Reinhart-King, C. A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-95294-9_6 · Cited by 153
Shen, J., Rees, T. W., Ji, L., & Chao, H. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214016 · Cited by 159
A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted Therapy
Zhang, T., Zhang, Z., Yue, Y., Hu, X., Huang, F., Shi, L., Liu, Y., & Guo, D. (2020) · Advanced Materials · doi:10.1002/adma.201908435 · Cited by 156
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 152
da Motta, L. L., Ledaki, I., Purshouse, K., Haider, S., De Bastiani, M. A., Baban, D., Morotti, M., Steers, G., Wigfield, S., Bridges, E., et al. (2017) · Oncogene · doi:10.1038/onc.2016.184 · Cited by 149
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 171
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Erkan, M., Kurtoğlu, M., & Kleeff, J. H. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1117386 · Cited by 165
Exploiting macrophages as targeted carrier to guide nanoparticles into glioma
Pang, L., Qin, J., Han, L., Zhao, W., Liang, J., Xie, Z., Yang, P., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9464 · Cited by 150
Nanomedicines for Cancer Therapy: Current status, Challenges and Future Prospects
Bor, G., Azmi, I. D. M., & Yaghmur, A. (2019) · Therapeutic Delivery · doi:10.4155/tde-2018-0062 · Cited by 157
Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells
Melzer, C., von der Ohe, J., Lehnert, H., Ungefroren, H., & Hass, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0595-x · Cited by 148
Wang, Y., Li, X., Zhao, S., Wang, B., Song, X., Xiao, J., & Lan, M. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214703 · Cited by 158
Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 145
Carbonic Anhydrase IX: Regulation and Role in Cancer
Benej, M., Pastoreková, S., & Pastorek, J. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-7359-2_11 · Cited by 161
Hypoxia: a Double-Edged Sword in Cancer Therapy
Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1245317 · Cited by 147
“Tumor hypoxic condition affects the biology of tumors such as apoptosis repression by alteration of pro-survival gene expression, genomic instability, neovasculation of tumor, enhancement of the downstream signaling pathway of tyrosine kinase receptor, and epithelial to mesenchymal transition (EMT) (2, 5).”
BackgroundMultifaceted control of DNA repair pathways by the hypoxic tumor microenvironment
Scanlon, S. E., & Glazer, P. M. (2015) · DNA Repair · doi:10.1016/j.dnarep.2015.04.030 · Cited by 147
Jiang, W., Zhang, Z., Wang, Q., Dou, J., Zhao, Y., Ma, Y., Liu, H., Xu, H., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01458 · Cited by 146
Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy
Zhang, C., Yan, L., Gu, Z., & Zhao, Y. (2019) · Chemical Science · doi:10.1039/c9sc02107h · Cited by 144
Zhang, J., Liu, H., Hu, X., Li, J., Liang, L., Zhang, X., & Tan, W. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03336 · Cited by 148
Transcriptional control of cancer metastasis
Ell, B. J., & Kang, Y. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.06.001 · Cited by 167
Bossler, F., Hoppe‐Seyler, K., & Hoppe‐Seyler, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092188 · Cited by 159
Near-infrared photodynamic and photothermal co-therapy based on organic small molecular dyes
Guo, S., Gu, D., Yang, Y., Tian, J., & Chen, X. S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02111-x · Cited by 168
Ju, E., Dong, K., Liu, Z., Pu, F., Ren, J., & Qu, X. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201403885 · Cited by 144
Reactive oxygen species-powered cancer immunotherapy: Current status and challenges
He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.040 · Cited by 150
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Mistry, I. N., Thomas, M., Calder, E. D. D., Conway, S. J., & Hammond, E. M. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.024 · Cited by 154
Zhao, D., Zhai, B., He, C., Tan, G., Jiang, X., Pan, S., Dong, X., Wei, Z., Ma, L., Qiao, H., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.026 · Cited by 141
Hypoxia as a biomarker for radioresistant cancer stem cells
Peitzsch, C., Perrin, R., Hill, R. P., Dubrovska, A., & Kurth, I. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.916841 · Cited by 140
A paper-based invasion assay: Assessing chemotaxis of cancer cells in gradients of oxygen
Mosadegh, B., Lockett, M. R., Minn, K. T., Simon, K. A., Gilbert, K., Hillier, S., Newsome, D., Li, H., Hall, A. B., Boucher, D. M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.012 · Cited by 142
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells
Jung, K. O., Youn, H., Lee, C., Kang, K. W., & Chung, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14247 · Cited by 148
Chafe, S. C., Vizeacoumar, F. S., Venkateswaran, G., Nemirovsky, O., Awrey, S. J., Brown, W. S., McDonald, P. C., Carta, F., Metcalfe, A. L., Karasinska, J. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0364 · Cited by 147
Gao, D.-Y., Lin, T.-T., Sung, Y., Liu, Y. C., Chiang, W., Chang, C.-C., Liu, J., & Chen, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.035 · Cited by 148
Anti-VEGF therapy in pituitary carcinoma
Ortiz, L. D., Syro, L. V., Scheithauer, B. W., Erşen, A., Uribe, H., Fadul, C. E., Rotondo, F., Horváth, É., & Kovács, K. (2011) · Pituitary · doi:10.1007/s11102-011-0346-8 · Cited by 142
Cao, Q., Zhou, D., Pan, Z., Yang, G., Zhang, H., Ji, L., & Mao, Z. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005362 · Cited by 145
Zhang, S., Chen, H., Wang, L., Qin, X., Jiang, B., Ji, S., Shen, X., & Liang, H. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202107076 · Cited by 139
Stimulus-responsive self-assembled prodrugs in cancer therapy
Dong, X., Brahma, R. K., Fang, C., & Yao, S. Q. (2022) · Chemical Science · doi:10.1039/d2sc01003h · Cited by 143
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Clostridium novyi-NT in cancer therapy
Staedtke, V., Roberts, N. J., Bai, R.-Y., & Zhou, S. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.01.003 · Cited by 153
A Versatile Pt‐Based Core–Shell Nanoplatform as a Nanofactory for Enhanced Tumor Therapy
Wang, X., Zeng, J., Zhang, M., Zeng, X., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801783 · Cited by 138
Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy
Wang, W., Cheng, Y., Yu, P., Wang, H., Zhang, Y., Xu, H., Ye, Q., Yuan, A., Hu, Y., & Wu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-09389-2 · Cited by 139
Zhang, B., Tang, B., Gao, J., Li, J., Kong, L., & Qin, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02492-9 · Cited by 156
Huang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 144
Tumor microenvironment-mediated chemoresistance in breast cancer
velaei, K., Samadi, N., Barazvan, B., & Soleimani Rad, J. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 138
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Shaked, Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.57 · Cited by 140
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, N., & Konopleva, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0895 · Cited by 138
Yang, G., Zhang, R., Liang, C., Zhao, H., Yi, X., Shen, S., Yang, K., Cheng, L., & Liu, Z. (2017) · Small · doi:10.1002/smll.201702664 · Cited by 139
Photodynamic therapy combined with immunotherapy: Recent advances and future research directions
Warszyńska, M., Repetowski, P., & Dąbrowski, J. M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215350 · Cited by 149
Engineering strategies to mimic the glioblastoma microenvironment
Rape, A. D., Ananthanarayanan, B., & Kumar, S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.08.012 · Cited by 143
Enhancement of tumor lethality of ROS in photodynamic therapy
Ming, L., Cheng, K. M., Chen, Y., Yang, R., & Chen, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3592 · Cited by 143
Oxygen self-sufficient photodynamic therapy
Wei, F., Rees, T. W., Liao, X., Ji, L., & Chao, H. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213714 · Cited by 138
Targeting the ATF4 pathway in cancer therapy
Singleton, D. C., & Harris, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.728207 · Cited by 135
Martínez‐González, A., Calvo, G. F., Pérez-Romasanta, L. A., & Pérez‐García, V. M. (2012) · Bulletin of Mathematical Biology · doi:10.1007/s11538-012-9786-1 · Cited by 144
Targeting Tumor Microenvironment by Small-Molecule Inhibitors
Zhong, S., Jeong, J.-H., Chen, Z., Chen, Z., & Luo, J.-L. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.001 · Cited by 134
miR-210: Fine-Tuning the Hypoxic Response
Ivan, M., & Huang, X. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_10 · Cited by 135
Li, J., Shi, K., Sabet, Z. F., Fu, W., Zhou, H., Xu, S., Liu, T., You, M., Cao, M., Xu, M., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax0937 · Cited by 134
Zhou, X., Liang, H., Jiang, P., Zhang, K. Y., Liu, S., Yang, T., Zhao, Q., Yang, L., Lv, W. Y., Yu, Q., et al. (2015) · Advanced Science · doi:10.1002/advs.201500155 · Cited by 137
Guo, T., Cui, L., Shen, J., Zhu, W., Xu, Y., & Qian, X. (2013) · Chemical Communications · doi:10.1039/c3cc45367g · Cited by 133
Cancer biomarker discovery: Current status and future perspectives
Mäbert, K., Cojoc, M., Peitzsch, C., Kurth, I., Souchelnytskyi, S., & Dubrovska, A. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.892229 · Cited by 152
Takahashi, S., Piao, W., Matsumura, Y., Komatsu, T., Ueno, T., Terai, T., Kamachi, T., Kohno, M., Nagano, T., & Hanaoka, K. (2012) · Journal of the American Chemical Society · doi:10.1021/ja310049d · Cited by 133
Zhang, Y., Yang, D., Chen, H., Lim, W. Q., Phua, F. S. Z., An, G., Yang, P., & Zhao, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.023 · Cited by 131
Chang, C.-C., Dinh, T. K., Lee, Y.-A., Wang, F., Sung, Y., Yu, P.-L., Chiu, S., Shih, Y., Wu, C., Huang, Y.-D., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c08473 · Cited by 133
Wang, H., Lv, B., Tang, Z., Zhang, M., Ge, W., Liu, Y., He, X., Zhao, K., Zheng, X., He, M., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02409 · Cited by 132
Fu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
Yu, F., Shi, W. S., Hu, Y., Li, X., & Ma, H. (2018) · Chemical Communications · doi:10.1039/c8cc02209g · Cited by 131
Mudassar, F., Shen, H., O’Neill, G., & Hau, E. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01724-6 · Cited by 129
Zhang, Q., Lou, Y., Zhang, J., Fu, Q., Wei, T., Sun, X., Chen, Q., Yang, J., Bai, X., & Liang, T. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0689-5 · Cited by 128
Morrot, A., da Fonseca, L. M., Salustiano, E. J., Gentile, L. B., Conde, L., Filardy, A. A., Franklim, T. N., da Costa, K. M., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00081 · Cited by 134
Gong, J., Zhou, S., & Yang, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030465 · Cited by 138
Sun, P., Deng, Q., Kang, L., Sun, Y., Ren, J., & Qu, X. (2020) · ACS Nano · doi:10.1021/acsnano.0c06290 · Cited by 128
Precise Subcellular Organelle Targeting for Boosting Endogenous‐Stimuli‐Mediated Tumor Therapy
Zhen, W., An, S., Wang, S., Hu, W., Li, Y., Jiang, X., & Li, J. (2021) · Advanced Materials · doi:10.1002/adma.202101572 · Cited by 130
The role of hypoxia-inducible factor-2 in digestive system cancers
Zhao, J., Du, F., Shen, G., Zheng, F., & Xu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.565 · Cited by 122
Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
Lan, J., Lu, H., Samanta, D., Salman, S., Lu, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 127
Recent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy
Wang, H., Li, J., Wang, Y., Gong, X., Xu, X., Wang, J., Li, Y., Sha, X., & Zhang, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.028 · Cited by 131
Li, J., Hu, Y., Hu, B., Wang, W., Xu, H., Hu, X., Ding, F., Li, H., Wang, K., Zhang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33920-7 · Cited by 147
Activatable Photosensitizers: From Fundamental Principles to Advanced Designs
Kwon, N., Weng, H., Rajora, M. A., & Zheng, G. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423348 · Cited by 137
In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation
Cao, J. X., Campbell, J., Liu, L., Mason, R. P., & Lippert, A. R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01096 · Cited by 128
Three‐dimensional cell culture model utilization in cancer stem cell research
Bielecka, Z. F., Maliszewska‐Olejniczak, K., SAFIR, I. J., Szczylik, C. A., & Czarnecka, A. M. (2016) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12293 · Cited by 139
Yang, J., Li, W., Luo, L., Jiang, M., Zhu, C., Qin, B., Yin, H., Yuan, X., Yin, X., Zhang, J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.004 · Cited by 127
Ultrasound Hyperthermia Technology for Radiosensitization
Zhu, L., Altman, M. B., Laszlo, A., Straube, W. L., Zoberi, I., Hallahan, D. E., & Chen, H. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.12.007 · Cited by 126
Activatable Small-Molecule Hydrogen Sulfide Donors
Levinn, C. M., Cerda, M. M., & Pluth, M. D. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7841 · Cited by 129
Rajendran, J. G., & Krohn, K. A. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.006 · Cited by 125
Convergent genomic signatures of high-altitude adaptation among domestic mammals
Wu, D., Yang, C., Wang, M., Dong, K., Yan, D., Hao, Z.-Q., Fan, S., Chu, S., Shen, Q., Jiang, L., et al. (2019) · National Science Review · doi:10.1093/nsr/nwz213 · Cited by 148
The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling
Moon, E. J., Mello, S. S., Li, C. G., Chi, J., Thakkar, K. N., Kirkland, J. G., LaGory, E. L., Lee, I. J., Diep, A. N., Miao, Y. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24631-6 · Cited by 144
Zhao, Q., Zheng, L., Gao, Y., Li, J., Wei, J., Zhang, M., Sun, J., Ouyang, J., & Na, N. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01532 · Cited by 128
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.